Global Oncolytic Virus Cancer Immunotherapy Market Research Report 2026(Status and Outlook)
Oncolytic virus is a special virus that can beneficially infect and kill cancer cells. These are deployed as part of cancer immunotherapy and work by selectively targeting cancer cells and performing oncolytics. Oncolytic viruses can not only kill cancer cells directly, but also stimulate patients' own anti-tumor immune response.
The global Oncolytic Virus Cancer Immunotherapy market size was estimated at USD 950.45 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 18.75% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Oncolytic Virus Cancer Immunotherapy market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Oncolytic Virus Cancer Immunotherapy market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Oncolytic Virus Cancer Immunotherapy market.
Global Oncolytic Virus Cancer Immunotherapy Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
AstraZeneca
Amgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co., Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
Market Segmentation (by Type)
Monoclonal Antibodies
Checkpoint Inhibitors
Oncoloytic Viral Therapies and Cancer Vaccines
Market Segmentation (by Application)
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others
Geographic Segmentation
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oncolytic Virus Cancer Immunotherapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Oncolytic Virus Cancer Immunotherapy, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Oncolytic Virus Cancer Immunotherapy market size was estimated at USD 950.45 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 18.75% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Oncolytic Virus Cancer Immunotherapy market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Oncolytic Virus Cancer Immunotherapy market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Oncolytic Virus Cancer Immunotherapy market.
Global Oncolytic Virus Cancer Immunotherapy Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
AstraZeneca
Amgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co., Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
Market Segmentation (by Type)
Monoclonal Antibodies
Checkpoint Inhibitors
Oncoloytic Viral Therapies and Cancer Vaccines
Market Segmentation (by Application)
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Oncolytic Virus Cancer Immunotherapy Market
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oncolytic Virus Cancer Immunotherapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Oncolytic Virus Cancer Immunotherapy, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Oncolytic Virus Cancer Immunotherapy
1.2 Key Market Segments
1.2.1 Oncolytic Virus Cancer Immunotherapy Segment by Type
1.2.2 Oncolytic Virus Cancer Immunotherapy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Oncolytic Virus Cancer Immunotherapy Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Oncolytic Virus Cancer Immunotherapy Product Life Cycle
3.3 Global Oncolytic Virus Cancer Immunotherapy Sales by Manufacturers (2020-2025)
3.4 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Manufacturers (2020-2025)
3.5 Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Oncolytic Virus Cancer Immunotherapy Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Oncolytic Virus Cancer Immunotherapy Market Competitive Situation and Trends
3.8.1 Oncolytic Virus Cancer Immunotherapy Market Concentration Rate
3.8.2 Global 5 and 10 Largest Oncolytic Virus Cancer Immunotherapy Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY INDUSTRY CHAIN ANALYSIS
4.1 Oncolytic Virus Cancer Immunotherapy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Oncolytic Virus Cancer Immunotherapy Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Oncolytic Virus Cancer Immunotherapy Market
5.7 ESG Ratings of Leading Companies
6 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Type (2020-2025)
6.3 Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (2020-2025)
6.4 Global Oncolytic Virus Cancer Immunotherapy Price by Type (2020-2025)
7 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Oncolytic Virus Cancer Immunotherapy Market Sales by Application (2020-2025)
7.3 Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD) by Application (2020-2025)
7.4 Global Oncolytic Virus Cancer Immunotherapy Sales Growth Rate by Application (2020-2025)
8 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SALES BY REGION
8.1 Global Oncolytic Virus Cancer Immunotherapy Sales by Region
8.1.1 Global Oncolytic Virus Cancer Immunotherapy Sales by Region
8.1.2 Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Region
8.2 Global Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.2.2 Global Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.3 North America
8.3.1 North America Oncolytic Virus Cancer Immunotherapy Sales by Country
8.3.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Oncolytic Virus Cancer Immunotherapy Sales by Country
8.4.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Oncolytic Virus Cancer Immunotherapy Sales by Region
8.5.2 Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Oncolytic Virus Cancer Immunotherapy Sales by Country
8.6.2 South America Oncolytic Virus Cancer Immunotherapy Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Oncolytic Virus Cancer Immunotherapy Sales by Region
8.7.2 Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET PRODUCTION BY REGION
9.1 Global Production of Oncolytic Virus Cancer Immunotherapy by Region(2020-2025)
9.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Region (2020-2025)
9.3 Global Oncolytic Virus Cancer Immunotherapy Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Oncolytic Virus Cancer Immunotherapy Production
9.4.1 North America Oncolytic Virus Cancer Immunotherapy Production Growth Rate (2020-2025)
9.4.2 North America Oncolytic Virus Cancer Immunotherapy Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Oncolytic Virus Cancer Immunotherapy Production
9.5.1 Europe Oncolytic Virus Cancer Immunotherapy Production Growth Rate (2020-2025)
9.5.2 Europe Oncolytic Virus Cancer Immunotherapy Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Oncolytic Virus Cancer Immunotherapy Production (2020-2025)
9.6.1 Japan Oncolytic Virus Cancer Immunotherapy Production Growth Rate (2020-2025)
9.6.2 Japan Oncolytic Virus Cancer Immunotherapy Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Oncolytic Virus Cancer Immunotherapy Production (2020-2025)
9.7.1 China Oncolytic Virus Cancer Immunotherapy Production Growth Rate (2020-2025)
9.7.2 China Oncolytic Virus Cancer Immunotherapy Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 AstraZeneca
10.1.1 AstraZeneca Basic Information
10.1.2 AstraZeneca Oncolytic Virus Cancer Immunotherapy Product Overview
10.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.1.4 AstraZeneca Business Overview
10.1.5 AstraZeneca SWOT Analysis
10.1.6 AstraZeneca Recent Developments
10.2 Amgen
10.2.1 Amgen Basic Information
10.2.2 Amgen Oncolytic Virus Cancer Immunotherapy Product Overview
10.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.2.4 Amgen Business Overview
10.2.5 Amgen SWOT Analysis
10.2.6 Amgen Recent Developments
10.3 F Hoffman-La Roche
10.3.1 F Hoffman-La Roche Basic Information
10.3.2 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product Overview
10.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.3.4 F Hoffman-La Roche Business Overview
10.3.5 F Hoffman-La Roche SWOT Analysis
10.3.6 F Hoffman-La Roche Recent Developments
10.4 Bristol-Myers Squibb
10.4.1 Bristol-Myers Squibb Basic Information
10.4.2 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product Overview
10.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.4.4 Bristol-Myers Squibb Business Overview
10.4.5 Bristol-Myers Squibb Recent Developments
10.5 Novartis AG
10.5.1 Novartis AG Basic Information
10.5.2 Novartis AG Oncolytic Virus Cancer Immunotherapy Product Overview
10.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.5.4 Novartis AG Business Overview
10.5.5 Novartis AG Recent Developments
10.6 Merck and Co., Inc.
10.6.1 Merck and Co., Inc. Basic Information
10.6.2 Merck and Co., Inc. Oncolytic Virus Cancer Immunotherapy Product Overview
10.6.3 Merck and Co., Inc. Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.6.4 Merck and Co., Inc. Business Overview
10.6.5 Merck and Co., Inc. Recent Developments
10.7 Pfizer
10.7.1 Pfizer Basic Information
10.7.2 Pfizer Oncolytic Virus Cancer Immunotherapy Product Overview
10.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.7.4 Pfizer Business Overview
10.7.5 Pfizer Recent Developments
10.8 Biovex
10.8.1 Biovex Basic Information
10.8.2 Biovex Oncolytic Virus Cancer Immunotherapy Product Overview
10.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.8.4 Biovex Business Overview
10.8.5 Biovex Recent Developments
10.9 Cell Genesys
10.9.1 Cell Genesys Basic Information
10.9.2 Cell Genesys Oncolytic Virus Cancer Immunotherapy Product Overview
10.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.9.4 Cell Genesys Business Overview
10.9.5 Cell Genesys Recent Developments
10.10 Crusade Laboratories
10.10.1 Crusade Laboratories Basic Information
10.10.2 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product Overview
10.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.10.4 Crusade Laboratories Business Overview
10.10.5 Crusade Laboratories Recent Developments
10.11 Genelux Corporation
10.11.1 Genelux Corporation Basic Information
10.11.2 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product Overview
10.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.11.4 Genelux Corporation Business Overview
10.11.5 Genelux Corporation Recent Developments
10.12 Lokon Pharma
10.12.1 Lokon Pharma Basic Information
10.12.2 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product Overview
10.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.12.4 Lokon Pharma Business Overview
10.12.5 Lokon Pharma Recent Developments
10.13 MultiVir
10.13.1 MultiVir Basic Information
10.13.2 MultiVir Oncolytic Virus Cancer Immunotherapy Product Overview
10.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.13.4 MultiVir Business Overview
10.13.5 MultiVir Recent Developments
11 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET FORECAST BY REGION
11.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast
11.2 Global Oncolytic Virus Cancer Immunotherapy Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country
11.2.3 Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Region
11.2.4 South America Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Oncolytic Virus Cancer Immunotherapy by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Oncolytic Virus Cancer Immunotherapy Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Oncolytic Virus Cancer Immunotherapy by Type (2026-2035)
12.1.2 Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Oncolytic Virus Cancer Immunotherapy by Type (2026-2035)
12.2 Global Oncolytic Virus Cancer Immunotherapy Market Forecast by Application (2026-2035)
12.2.1 Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) Forecast by Application
12.2.2 Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Oncolytic Virus Cancer Immunotherapy
1.2 Key Market Segments
1.2.1 Oncolytic Virus Cancer Immunotherapy Segment by Type
1.2.2 Oncolytic Virus Cancer Immunotherapy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Oncolytic Virus Cancer Immunotherapy Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Oncolytic Virus Cancer Immunotherapy Product Life Cycle
3.3 Global Oncolytic Virus Cancer Immunotherapy Sales by Manufacturers (2020-2025)
3.4 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Manufacturers (2020-2025)
3.5 Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Oncolytic Virus Cancer Immunotherapy Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Oncolytic Virus Cancer Immunotherapy Market Competitive Situation and Trends
3.8.1 Oncolytic Virus Cancer Immunotherapy Market Concentration Rate
3.8.2 Global 5 and 10 Largest Oncolytic Virus Cancer Immunotherapy Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY INDUSTRY CHAIN ANALYSIS
4.1 Oncolytic Virus Cancer Immunotherapy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Oncolytic Virus Cancer Immunotherapy Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Oncolytic Virus Cancer Immunotherapy Market
5.7 ESG Ratings of Leading Companies
6 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Type (2020-2025)
6.3 Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (2020-2025)
6.4 Global Oncolytic Virus Cancer Immunotherapy Price by Type (2020-2025)
7 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Oncolytic Virus Cancer Immunotherapy Market Sales by Application (2020-2025)
7.3 Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD) by Application (2020-2025)
7.4 Global Oncolytic Virus Cancer Immunotherapy Sales Growth Rate by Application (2020-2025)
8 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET SALES BY REGION
8.1 Global Oncolytic Virus Cancer Immunotherapy Sales by Region
8.1.1 Global Oncolytic Virus Cancer Immunotherapy Sales by Region
8.1.2 Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Region
8.2 Global Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.2.2 Global Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.3 North America
8.3.1 North America Oncolytic Virus Cancer Immunotherapy Sales by Country
8.3.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Oncolytic Virus Cancer Immunotherapy Sales by Country
8.4.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Oncolytic Virus Cancer Immunotherapy Sales by Region
8.5.2 Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Oncolytic Virus Cancer Immunotherapy Sales by Country
8.6.2 South America Oncolytic Virus Cancer Immunotherapy Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Oncolytic Virus Cancer Immunotherapy Sales by Region
8.7.2 Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET PRODUCTION BY REGION
9.1 Global Production of Oncolytic Virus Cancer Immunotherapy by Region(2020-2025)
9.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Region (2020-2025)
9.3 Global Oncolytic Virus Cancer Immunotherapy Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Oncolytic Virus Cancer Immunotherapy Production
9.4.1 North America Oncolytic Virus Cancer Immunotherapy Production Growth Rate (2020-2025)
9.4.2 North America Oncolytic Virus Cancer Immunotherapy Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Oncolytic Virus Cancer Immunotherapy Production
9.5.1 Europe Oncolytic Virus Cancer Immunotherapy Production Growth Rate (2020-2025)
9.5.2 Europe Oncolytic Virus Cancer Immunotherapy Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Oncolytic Virus Cancer Immunotherapy Production (2020-2025)
9.6.1 Japan Oncolytic Virus Cancer Immunotherapy Production Growth Rate (2020-2025)
9.6.2 Japan Oncolytic Virus Cancer Immunotherapy Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Oncolytic Virus Cancer Immunotherapy Production (2020-2025)
9.7.1 China Oncolytic Virus Cancer Immunotherapy Production Growth Rate (2020-2025)
9.7.2 China Oncolytic Virus Cancer Immunotherapy Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 AstraZeneca
10.1.1 AstraZeneca Basic Information
10.1.2 AstraZeneca Oncolytic Virus Cancer Immunotherapy Product Overview
10.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.1.4 AstraZeneca Business Overview
10.1.5 AstraZeneca SWOT Analysis
10.1.6 AstraZeneca Recent Developments
10.2 Amgen
10.2.1 Amgen Basic Information
10.2.2 Amgen Oncolytic Virus Cancer Immunotherapy Product Overview
10.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.2.4 Amgen Business Overview
10.2.5 Amgen SWOT Analysis
10.2.6 Amgen Recent Developments
10.3 F Hoffman-La Roche
10.3.1 F Hoffman-La Roche Basic Information
10.3.2 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product Overview
10.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.3.4 F Hoffman-La Roche Business Overview
10.3.5 F Hoffman-La Roche SWOT Analysis
10.3.6 F Hoffman-La Roche Recent Developments
10.4 Bristol-Myers Squibb
10.4.1 Bristol-Myers Squibb Basic Information
10.4.2 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product Overview
10.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.4.4 Bristol-Myers Squibb Business Overview
10.4.5 Bristol-Myers Squibb Recent Developments
10.5 Novartis AG
10.5.1 Novartis AG Basic Information
10.5.2 Novartis AG Oncolytic Virus Cancer Immunotherapy Product Overview
10.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.5.4 Novartis AG Business Overview
10.5.5 Novartis AG Recent Developments
10.6 Merck and Co., Inc.
10.6.1 Merck and Co., Inc. Basic Information
10.6.2 Merck and Co., Inc. Oncolytic Virus Cancer Immunotherapy Product Overview
10.6.3 Merck and Co., Inc. Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.6.4 Merck and Co., Inc. Business Overview
10.6.5 Merck and Co., Inc. Recent Developments
10.7 Pfizer
10.7.1 Pfizer Basic Information
10.7.2 Pfizer Oncolytic Virus Cancer Immunotherapy Product Overview
10.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.7.4 Pfizer Business Overview
10.7.5 Pfizer Recent Developments
10.8 Biovex
10.8.1 Biovex Basic Information
10.8.2 Biovex Oncolytic Virus Cancer Immunotherapy Product Overview
10.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.8.4 Biovex Business Overview
10.8.5 Biovex Recent Developments
10.9 Cell Genesys
10.9.1 Cell Genesys Basic Information
10.9.2 Cell Genesys Oncolytic Virus Cancer Immunotherapy Product Overview
10.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.9.4 Cell Genesys Business Overview
10.9.5 Cell Genesys Recent Developments
10.10 Crusade Laboratories
10.10.1 Crusade Laboratories Basic Information
10.10.2 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product Overview
10.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.10.4 Crusade Laboratories Business Overview
10.10.5 Crusade Laboratories Recent Developments
10.11 Genelux Corporation
10.11.1 Genelux Corporation Basic Information
10.11.2 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product Overview
10.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.11.4 Genelux Corporation Business Overview
10.11.5 Genelux Corporation Recent Developments
10.12 Lokon Pharma
10.12.1 Lokon Pharma Basic Information
10.12.2 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product Overview
10.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.12.4 Lokon Pharma Business Overview
10.12.5 Lokon Pharma Recent Developments
10.13 MultiVir
10.13.1 MultiVir Basic Information
10.13.2 MultiVir Oncolytic Virus Cancer Immunotherapy Product Overview
10.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Product Market Performance
10.13.4 MultiVir Business Overview
10.13.5 MultiVir Recent Developments
11 ONCOLYTIC VIRUS CANCER IMMUNOTHERAPY MARKET FORECAST BY REGION
11.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast
11.2 Global Oncolytic Virus Cancer Immunotherapy Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country
11.2.3 Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Region
11.2.4 South America Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Oncolytic Virus Cancer Immunotherapy by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Oncolytic Virus Cancer Immunotherapy Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Oncolytic Virus Cancer Immunotherapy by Type (2026-2035)
12.1.2 Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Oncolytic Virus Cancer Immunotherapy by Type (2026-2035)
12.2 Global Oncolytic Virus Cancer Immunotherapy Market Forecast by Application (2026-2035)
12.2.1 Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) Forecast by Application
12.2.2 Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (M USD)
Table 4. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application
Table 5. Oncolytic Virus Cancer Immunotherapy Market Size Comparison by Region (M USD)
Table 6. Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Oncolytic Virus Cancer Immunotherapy Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2025)
Table 11. Global Market Oncolytic Virus Cancer Immunotherapy Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Oncolytic Virus Cancer Immunotherapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Oncolytic Virus Cancer Immunotherapy Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Oncolytic Virus Cancer Immunotherapy Sales by Type (K Units)
Table 27. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (M USD)
Table 28. Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) by Type (2020-2025)
Table 29. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Type (2020-2025)
Table 30. Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD) by Type (2020-2025)
Table 31. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type (2020-2025)
Table 32. Global Oncolytic Virus Cancer Immunotherapy Price (USD/Unit) by Type (2020-2025)
Table 33. Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) by Application
Table 34. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application
Table 35. Global Oncolytic Virus Cancer Immunotherapy Sales by Application (2020-2025) & (K Units)
Table 36. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Application (2020-2025)
Table 37. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application (2020-2025) & (M USD)
Table 38. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application (2020-2025)
Table 39. Global Oncolytic Virus Cancer Immunotherapy Sales Growth Rate by Application (2020-2025)
Table 40. Global Oncolytic Virus Cancer Immunotherapy Sales by Region (2020-2025) & (K Units)
Table 41. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Region (2020-2025)
Table 42. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2020-2025) & (M USD)
Table 43. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2020-2025)
Table 44. North America Oncolytic Virus Cancer Immunotherapy Sales by Country (2020-2025) & (K Units)
Table 45. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Oncolytic Virus Cancer Immunotherapy Sales by Country (2020-2025) & (K Units)
Table 47. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Oncolytic Virus Cancer Immunotherapy Sales by Region (2020-2025) & (K Units)
Table 49. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2020-2025) & (M USD)
Table 50. South America Oncolytic Virus Cancer Immunotherapy Sales by Country (2020-2025) & (K Units)
Table 51. South America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Sales by Region (2020-2025) & (K Units)
Table 53. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Region (2020-2025) & (M USD)
Table 54. Global Oncolytic Virus Cancer Immunotherapy Production (K Units) by Region(2020-2025)
Table 55. Global Oncolytic Virus Cancer Immunotherapy Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Region (2020-2025)
Table 57. Global Oncolytic Virus Cancer Immunotherapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. North America Oncolytic Virus Cancer Immunotherapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Europe Oncolytic Virus Cancer Immunotherapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Japan Oncolytic Virus Cancer Immunotherapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. China Oncolytic Virus Cancer Immunotherapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 62. AstraZeneca Basic Information
Table 63. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product Overview
Table 64. AstraZeneca Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. AstraZeneca Business Overview
Table 66. AstraZeneca SWOT Analysis
Table 67. AstraZeneca Recent Developments
Table 68. Amgen Basic Information
Table 69. Amgen Oncolytic Virus Cancer Immunotherapy Product Overview
Table 70. Amgen Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 71. Amgen Business Overview
Table 72. Amgen SWOT Analysis
Table 73. Amgen Recent Developments
Table 74. F Hoffman-La Roche Basic Information
Table 75. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product Overview
Table 76. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. F Hoffman-La Roche Business Overview
Table 78. F Hoffman-La Roche SWOT Analysis
Table 79. F Hoffman-La Roche Recent Developments
Table 80. Bristol-Myers Squibb Basic Information
Table 81. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product Overview
Table 82. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Bristol-Myers Squibb Business Overview
Table 84. Bristol-Myers Squibb Recent Developments
Table 85. Novartis AG Basic Information
Table 86. Novartis AG Oncolytic Virus Cancer Immunotherapy Product Overview
Table 87. Novartis AG Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Novartis AG Business Overview
Table 89. Novartis AG Recent Developments
Table 90. Merck and Co., Inc. Basic Information
Table 91. Merck and Co., Inc. Oncolytic Virus Cancer Immunotherapy Product Overview
Table 92. Merck and Co., Inc. Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Merck and Co., Inc. Business Overview
Table 94. Merck and Co., Inc. Recent Developments
Table 95. Pfizer Basic Information
Table 96. Pfizer Oncolytic Virus Cancer Immunotherapy Product Overview
Table 97. Pfizer Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Pfizer Business Overview
Table 99. Pfizer Recent Developments
Table 100. Biovex Basic Information
Table 101. Biovex Oncolytic Virus Cancer Immunotherapy Product Overview
Table 102. Biovex Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Biovex Business Overview
Table 104. Biovex Recent Developments
Table 105. Cell Genesys Basic Information
Table 106. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product Overview
Table 107. Cell Genesys Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Cell Genesys Business Overview
Table 109. Cell Genesys Recent Developments
Table 110. Crusade Laboratories Basic Information
Table 111. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product Overview
Table 112. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Crusade Laboratories Business Overview
Table 114. Crusade Laboratories Recent Developments
Table 115. Genelux Corporation Basic Information
Table 116. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product Overview
Table 117. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Genelux Corporation Business Overview
Table 119. Genelux Corporation Recent Developments
Table 120. Lokon Pharma Basic Information
Table 121. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product Overview
Table 122. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Lokon Pharma Business Overview
Table 124. Lokon Pharma Recent Developments
Table 125. MultiVir Basic Information
Table 126. MultiVir Oncolytic Virus Cancer Immunotherapy Product Overview
Table 127. MultiVir Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. MultiVir Business Overview
Table 129. MultiVir Recent Developments
Table 130. Global Oncolytic Virus Cancer Immunotherapy Sales Forecast by Region (2026-2035) & (K Units)
Table 131. Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Region (2026-2035) & (M USD)
Table 132. North America Oncolytic Virus Cancer Immunotherapy Sales Forecast by Country (2026-2035) & (K Units)
Table 133. North America Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 134. Europe Oncolytic Virus Cancer Immunotherapy Sales Forecast by Country (2026-2035) & (K Units)
Table 135. Europe Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 136. Asia Pacific Oncolytic Virus Cancer Immunotherapy Sales Forecast by Region (2026-2035) & (K Units)
Table 137. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Region (2026-2035) & (M USD)
Table 138. South America Oncolytic Virus Cancer Immunotherapy Sales Forecast by Country (2026-2035) & (K Units)
Table 139. South America Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 140. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Sales Forecast by Country (2026-2035) & (Units)
Table 141. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 142. Global Oncolytic Virus Cancer Immunotherapy Sales Forecast by Type (2026-2035) & (K Units)
Table 143. Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Type (2026-2035) & (M USD)
Table 144. Global Oncolytic Virus Cancer Immunotherapy Price Forecast by Type (2026-2035) & (USD/Unit)
Table 145. Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) Forecast by Application (2026-2035)
Table 146. Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (M USD)
Table 4. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application
Table 5. Oncolytic Virus Cancer Immunotherapy Market Size Comparison by Region (M USD)
Table 6. Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Oncolytic Virus Cancer Immunotherapy Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2025)
Table 11. Global Market Oncolytic Virus Cancer Immunotherapy Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Oncolytic Virus Cancer Immunotherapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Oncolytic Virus Cancer Immunotherapy Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Oncolytic Virus Cancer Immunotherapy Sales by Type (K Units)
Table 27. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (M USD)
Table 28. Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) by Type (2020-2025)
Table 29. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Type (2020-2025)
Table 30. Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD) by Type (2020-2025)
Table 31. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type (2020-2025)
Table 32. Global Oncolytic Virus Cancer Immunotherapy Price (USD/Unit) by Type (2020-2025)
Table 33. Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) by Application
Table 34. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application
Table 35. Global Oncolytic Virus Cancer Immunotherapy Sales by Application (2020-2025) & (K Units)
Table 36. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Application (2020-2025)
Table 37. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application (2020-2025) & (M USD)
Table 38. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application (2020-2025)
Table 39. Global Oncolytic Virus Cancer Immunotherapy Sales Growth Rate by Application (2020-2025)
Table 40. Global Oncolytic Virus Cancer Immunotherapy Sales by Region (2020-2025) & (K Units)
Table 41. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Region (2020-2025)
Table 42. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2020-2025) & (M USD)
Table 43. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2020-2025)
Table 44. North America Oncolytic Virus Cancer Immunotherapy Sales by Country (2020-2025) & (K Units)
Table 45. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Oncolytic Virus Cancer Immunotherapy Sales by Country (2020-2025) & (K Units)
Table 47. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Oncolytic Virus Cancer Immunotherapy Sales by Region (2020-2025) & (K Units)
Table 49. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2020-2025) & (M USD)
Table 50. South America Oncolytic Virus Cancer Immunotherapy Sales by Country (2020-2025) & (K Units)
Table 51. South America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Sales by Region (2020-2025) & (K Units)
Table 53. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Region (2020-2025) & (M USD)
Table 54. Global Oncolytic Virus Cancer Immunotherapy Production (K Units) by Region(2020-2025)
Table 55. Global Oncolytic Virus Cancer Immunotherapy Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Region (2020-2025)
Table 57. Global Oncolytic Virus Cancer Immunotherapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. North America Oncolytic Virus Cancer Immunotherapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Europe Oncolytic Virus Cancer Immunotherapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Japan Oncolytic Virus Cancer Immunotherapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. China Oncolytic Virus Cancer Immunotherapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 62. AstraZeneca Basic Information
Table 63. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product Overview
Table 64. AstraZeneca Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. AstraZeneca Business Overview
Table 66. AstraZeneca SWOT Analysis
Table 67. AstraZeneca Recent Developments
Table 68. Amgen Basic Information
Table 69. Amgen Oncolytic Virus Cancer Immunotherapy Product Overview
Table 70. Amgen Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 71. Amgen Business Overview
Table 72. Amgen SWOT Analysis
Table 73. Amgen Recent Developments
Table 74. F Hoffman-La Roche Basic Information
Table 75. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product Overview
Table 76. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. F Hoffman-La Roche Business Overview
Table 78. F Hoffman-La Roche SWOT Analysis
Table 79. F Hoffman-La Roche Recent Developments
Table 80. Bristol-Myers Squibb Basic Information
Table 81. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product Overview
Table 82. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Bristol-Myers Squibb Business Overview
Table 84. Bristol-Myers Squibb Recent Developments
Table 85. Novartis AG Basic Information
Table 86. Novartis AG Oncolytic Virus Cancer Immunotherapy Product Overview
Table 87. Novartis AG Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Novartis AG Business Overview
Table 89. Novartis AG Recent Developments
Table 90. Merck and Co., Inc. Basic Information
Table 91. Merck and Co., Inc. Oncolytic Virus Cancer Immunotherapy Product Overview
Table 92. Merck and Co., Inc. Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Merck and Co., Inc. Business Overview
Table 94. Merck and Co., Inc. Recent Developments
Table 95. Pfizer Basic Information
Table 96. Pfizer Oncolytic Virus Cancer Immunotherapy Product Overview
Table 97. Pfizer Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Pfizer Business Overview
Table 99. Pfizer Recent Developments
Table 100. Biovex Basic Information
Table 101. Biovex Oncolytic Virus Cancer Immunotherapy Product Overview
Table 102. Biovex Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Biovex Business Overview
Table 104. Biovex Recent Developments
Table 105. Cell Genesys Basic Information
Table 106. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product Overview
Table 107. Cell Genesys Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Cell Genesys Business Overview
Table 109. Cell Genesys Recent Developments
Table 110. Crusade Laboratories Basic Information
Table 111. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product Overview
Table 112. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Crusade Laboratories Business Overview
Table 114. Crusade Laboratories Recent Developments
Table 115. Genelux Corporation Basic Information
Table 116. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product Overview
Table 117. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Genelux Corporation Business Overview
Table 119. Genelux Corporation Recent Developments
Table 120. Lokon Pharma Basic Information
Table 121. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product Overview
Table 122. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Lokon Pharma Business Overview
Table 124. Lokon Pharma Recent Developments
Table 125. MultiVir Basic Information
Table 126. MultiVir Oncolytic Virus Cancer Immunotherapy Product Overview
Table 127. MultiVir Oncolytic Virus Cancer Immunotherapy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. MultiVir Business Overview
Table 129. MultiVir Recent Developments
Table 130. Global Oncolytic Virus Cancer Immunotherapy Sales Forecast by Region (2026-2035) & (K Units)
Table 131. Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Region (2026-2035) & (M USD)
Table 132. North America Oncolytic Virus Cancer Immunotherapy Sales Forecast by Country (2026-2035) & (K Units)
Table 133. North America Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 134. Europe Oncolytic Virus Cancer Immunotherapy Sales Forecast by Country (2026-2035) & (K Units)
Table 135. Europe Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 136. Asia Pacific Oncolytic Virus Cancer Immunotherapy Sales Forecast by Region (2026-2035) & (K Units)
Table 137. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Region (2026-2035) & (M USD)
Table 138. South America Oncolytic Virus Cancer Immunotherapy Sales Forecast by Country (2026-2035) & (K Units)
Table 139. South America Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 140. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Sales Forecast by Country (2026-2035) & (Units)
Table 141. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 142. Global Oncolytic Virus Cancer Immunotherapy Sales Forecast by Type (2026-2035) & (K Units)
Table 143. Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Type (2026-2035) & (M USD)
Table 144. Global Oncolytic Virus Cancer Immunotherapy Price Forecast by Type (2026-2035) & (USD/Unit)
Table 145. Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) Forecast by Application (2026-2035)
Table 146. Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Oncolytic Virus Cancer Immunotherapy
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD), 2025-2035
Figure 5. Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD) (2020-2035)
Figure 6. Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Oncolytic Virus Cancer Immunotherapy Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Oncolytic Virus Cancer Immunotherapy Product Life Cycle
Figure 13. Oncolytic Virus Cancer Immunotherapy Sales Share by Manufacturers in 2025
Figure 14. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Manufacturers in 2025
Figure 15. Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Oncolytic Virus Cancer Immunotherapy Average Price (USD/Unit) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2025
Figure 18. Industry Chain Map of Oncolytic Virus Cancer Immunotherapy
Figure 19. Global Oncolytic Virus Cancer Immunotherapy Market PEST Analysis
Figure 20. Global Oncolytic Virus Cancer Immunotherapy Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type
Figure 27. Sales Market Share of Oncolytic Virus Cancer Immunotherapy by Type (2020-2025)
Figure 28. Sales Market Share of Oncolytic Virus Cancer Immunotherapy by Type in 2025
Figure 29. Market Share of Oncolytic Virus Cancer Immunotherapy by Type (2020-2025)
Figure 30. Market Share of Oncolytic Virus Cancer Immunotherapy by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application
Figure 33. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Application (2020-2025)
Figure 34. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Application in 2025
Figure 35. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application (2020-2025)
Figure 36. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application in 2025
Figure 37. Global Oncolytic Virus Cancer Immunotherapy Sales Growth Rate by Application (2020-2025)
Figure 38. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Region (2020-2025)
Figure 39. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2020-2025)
Figure 40. North America Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Oncolytic Virus Cancer Immunotherapy Sales Market Share by Country in 2024
Figure 43. North America Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country in 2024
Figure 45. U.S. Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Oncolytic Virus Cancer Immunotherapy Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Oncolytic Virus Cancer Immunotherapy Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Oncolytic Virus Cancer Immunotherapy Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Oncolytic Virus Cancer Immunotherapy Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Oncolytic Virus Cancer Immunotherapy Sales Market Share by Country in 2024
Figure 53. Europe Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country in 2024
Figure 55. Germany Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Oncolytic Virus Cancer Immunotherapy Sales Market Share by Region in 2024
Figure 67. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region in 2024
Figure 68. China Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (K Units)
Figure 79. South America Oncolytic Virus Cancer Immunotherapy Sales Market Share by Country in 2024
Figure 80. South America Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (M USD)
Figure 81. South America Oncolytic Virus Cancer Immunotherapy Market Size by Country in 2024
Figure 82. Brazil Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Region in 2024
Figure 92. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Oncolytic Virus Cancer Immunotherapy Production Market Share by Region (2020-2025)
Figure 103. North America Oncolytic Virus Cancer Immunotherapy Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Oncolytic Virus Cancer Immunotherapy Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Oncolytic Virus Cancer Immunotherapy Production (K Units) Growth Rate (2020-2025)
Figure 106. China Oncolytic Virus Cancer Immunotherapy Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Oncolytic Virus Cancer Immunotherapy Sales Forecast by Volume (2020-2035) & (K Units)
Figure 108. Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Oncolytic Virus Cancer Immunotherapy Market Share Forecast by Type (2026-2035)
Figure 111. Global Oncolytic Virus Cancer Immunotherapy Sales Forecast by Application (2026-2035)
Figure 112. Global Oncolytic Virus Cancer Immunotherapy Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Oncolytic Virus Cancer Immunotherapy
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD), 2025-2035
Figure 5. Global Oncolytic Virus Cancer Immunotherapy Market Size (M USD) (2020-2035)
Figure 6. Global Oncolytic Virus Cancer Immunotherapy Sales (K Units) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Oncolytic Virus Cancer Immunotherapy Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Oncolytic Virus Cancer Immunotherapy Product Life Cycle
Figure 13. Oncolytic Virus Cancer Immunotherapy Sales Share by Manufacturers in 2025
Figure 14. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Manufacturers in 2025
Figure 15. Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Oncolytic Virus Cancer Immunotherapy Average Price (USD/Unit) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2025
Figure 18. Industry Chain Map of Oncolytic Virus Cancer Immunotherapy
Figure 19. Global Oncolytic Virus Cancer Immunotherapy Market PEST Analysis
Figure 20. Global Oncolytic Virus Cancer Immunotherapy Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type
Figure 27. Sales Market Share of Oncolytic Virus Cancer Immunotherapy by Type (2020-2025)
Figure 28. Sales Market Share of Oncolytic Virus Cancer Immunotherapy by Type in 2025
Figure 29. Market Share of Oncolytic Virus Cancer Immunotherapy by Type (2020-2025)
Figure 30. Market Share of Oncolytic Virus Cancer Immunotherapy by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application
Figure 33. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Application (2020-2025)
Figure 34. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Application in 2025
Figure 35. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application (2020-2025)
Figure 36. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application in 2025
Figure 37. Global Oncolytic Virus Cancer Immunotherapy Sales Growth Rate by Application (2020-2025)
Figure 38. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share by Region (2020-2025)
Figure 39. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2020-2025)
Figure 40. North America Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Oncolytic Virus Cancer Immunotherapy Sales Market Share by Country in 2024
Figure 43. North America Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country in 2024
Figure 45. U.S. Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Oncolytic Virus Cancer Immunotherapy Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Oncolytic Virus Cancer Immunotherapy Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Oncolytic Virus Cancer Immunotherapy Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Oncolytic Virus Cancer Immunotherapy Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Oncolytic Virus Cancer Immunotherapy Sales Market Share by Country in 2024
Figure 53. Europe Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country in 2024
Figure 55. Germany Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Oncolytic Virus Cancer Immunotherapy Sales Market Share by Region in 2024
Figure 67. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region in 2024
Figure 68. China Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (K Units)
Figure 79. South America Oncolytic Virus Cancer Immunotherapy Sales Market Share by Country in 2024
Figure 80. South America Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (M USD)
Figure 81. South America Oncolytic Virus Cancer Immunotherapy Market Size by Country in 2024
Figure 82. Brazil Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Region in 2024
Figure 92. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Oncolytic Virus Cancer Immunotherapy Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Oncolytic Virus Cancer Immunotherapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Oncolytic Virus Cancer Immunotherapy Production Market Share by Region (2020-2025)
Figure 103. North America Oncolytic Virus Cancer Immunotherapy Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Oncolytic Virus Cancer Immunotherapy Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Oncolytic Virus Cancer Immunotherapy Production (K Units) Growth Rate (2020-2025)
Figure 106. China Oncolytic Virus Cancer Immunotherapy Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Oncolytic Virus Cancer Immunotherapy Sales Forecast by Volume (2020-2035) & (K Units)
Figure 108. Global Oncolytic Virus Cancer Immunotherapy Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Oncolytic Virus Cancer Immunotherapy Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Oncolytic Virus Cancer Immunotherapy Market Share Forecast by Type (2026-2035)
Figure 111. Global Oncolytic Virus Cancer Immunotherapy Sales Forecast by Application (2026-2035)
Figure 112. Global Oncolytic Virus Cancer Immunotherapy Market Share Forecast by Application (2026-2035)
